Condition: Duchenne Muscular Dystrophy · Sponsor: Sarepta Therapeutics, Inc.
Cohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed. This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with Duchenne Muscular Dystrophy (DMD). The maximum participant duration for this study is 156 weeks.
This description comes directly from the study's public registry record.
Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4 · 1-888-SAREPTA (1-888-727-3782) · SareptAlly@Sarepta.com
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| University of California, Davis | Sacramento, California, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Active Not Recruiting |
| Neurology Rare Disease Center | Flower Mound, Texas, United States | Recruiting |
| Children's Hospital of The King's Daughters | Norfolk, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04626674